Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference
Evercore ISI3rd Annual HEALTHCONx Conferenceon Tuesday, December 1at 2:40 p.m. ET( 11:40 a.m. PT/ 7:40 p.m. GMT)
Webcast of the presentation may be accessed by visiting the "Investors" section of
In pursuit of our purpose, we apply insights and innovation at each stage of our business and utilize our internal capabilities and those of partners around the world. We apply organ-selective expertise to biologically compelling targets to discover and develop medicines designed to treat underserved localized diseases and to limit systemic exposure, in order to maximize patient benefit and minimize risk. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Our pipeline of internally discovered programs is targeted to address significant patient needs.
We have an economic interest in potential future payments from
For more information, please visit www.theravance.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-3rd-annual-evercore-isi-healthconx-conference-301174097.html